WO2002005616A1 - Novel 6-phenylphenanthridines - Google Patents
Novel 6-phenylphenanthridines Download PDFInfo
- Publication number
- WO2002005616A1 WO2002005616A1 PCT/EP2001/007829 EP0107829W WO0205616A1 WO 2002005616 A1 WO2002005616 A1 WO 2002005616A1 EP 0107829 W EP0107829 W EP 0107829W WO 0205616 A1 WO0205616 A1 WO 0205616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- alkoxy
- substituted
- formula
- Prior art date
Links
- 0 *CC(*)(C(*)C1c2cc(*)c(*)cc2)C(*)(*)C(*)C1N Chemical compound *CC(*)(C(*)C1c2cc(*)c(*)cc2)C(*)(*)C(*)C1N 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
Definitions
- the invention relates to novel 6-phenylphenanthridines, which are used in the pharmaceutical industry for the production of medicaments.
- the invention thus relates to compounds of the formula I,
- R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
- R2 is hydroxyl, 1-4C-aikoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy, or in which R1 and R2 together are a 1-2C-alkylenedioxy group,
- R3 is hydrogen or 1-4C-alkyl
- R31 is hydrogen or 1-4C-alkyl, or in which
- R3 and R31 together are a 1-4C-alkylene group
- R4 is hydrogen or 1-4C-alkyl
- R5 is hydrogen
- R51 is hydrogen, or in which
- R6 is S0 2 N(R7)R8, COOR9, CON(R10)R11 or a R15-substituted tetrazol-5-yl radical, where
- R7 and R8 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycioalkylmethyl or a phenyl radical which is unsubstituted or substituted by R12 and/or R13, or where R7 and R8 together and including the nitrogen atom to which both are bonded are a 1-pyrrolidinyl, 1-piperidyl, 1-hexahydroazepinyI or 4-morpholinyl radical, R9 is hydrogen, 1-7C-alkyl, 3-7C-cycloaikyl or 3-7C-cycloalkylmethyl, and where either R10 and R11 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl, or
- R10 is hydrogen or 1-4C-alkyl
- R11 is a phenyl radical which is unsubstituted or substituted by R12 and/or R13 or a pyridyl radical which is unsubstituted or substituted by R14, where R12 is hydroxyl, halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R13 is hydroxyl, halogen, nitro, cyano, carboxyl, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyI, 1-4C-alkyIcarbonyIoxy, amino, mono- or di-1-4C-alkylamino, amino- carbonyl, mono- or di-1-4C-alkylaminocarbonyl or completely or predominantly fluorine- substituted 1-4C-alkoxy,
- R14 is halogen, nitro, carboxyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkyl, trifluoromethyl or completely or predominantly fluorine-substituted 1-4C-alkoxy
- R15 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl or Ar-1-4C-alkyl where Ar is a phenyl radical which is unsubstituted or substituted by R16 and/or R17, and R16 and R17 independently of one another are halogen, nitro, cyano, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,
- R18 is hydroxyl, halogen, nitro, amino, 1-,4C-alkyI or 1-4C-alkoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
- 1-7C-Alkyl represents straight-chain or branched alkyl radicals having 1 to 7 carbon atoms. Examples which may be mentioned are the heptyl, isoheptyl (5-methyihexyI), hexyl, isohexyl (4-methylpentyl), neohexyl (3,3-dimethylbutyI), pentyl, isopentyl (3-methylbutyl), neopentyl (2,2-dimethylpropyl), butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and the methyl radical.
- 1-4C-Alkyl represents a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl and preferably the ethyl and methyl radicals.
- 1-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy radicals.
- 3-7C-Cycloalkoxy represents cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cyclo- heptyloxy, of which cyclopropyloxy, cyclobutyloxy and cyclopentyloxy are preferred.
- 3-7C-Cycloalkylmethoxy represents cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cy- clohexylmethoxy and cycloheptylmethoxy, of which cyclopropylmethoxy, cyclobutylmethoxy and cyclopentylmethoxy are preferred.
- fluorine-substituted 1-4C-alkoxy for example, the 2,2,3,3,3-penta- fluoropropoxy, the perfluoroethoxy, the 1 ,2,2-trifluoroethoxy, in particular the 1 ,1 ,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and preferably the difluoromethoxy radicals may be mentioned.
- "Predominantly" in this connection means that more than half of the hydrogen atoms of the 1-4C-alkoxy radical are replaced by fluorine atoms.
- 1-2C-Alkylenedioxy represents, for example, the methylenedioxy [-0-CH 2 -0-] and the ethylenedioxy [-0-CH 2 -CH 2 -0-] radicals.
- R3 and R31 together have the meaning 1-4C-alkylene
- the positions 1 and 4 in compounds of the formula I are linked to one another by a 1-4C-alkylene bridge, 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms.
- 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms. Examples which may be mentioned are the radicals methylene [-CH 2 -], ethylene [-CH 2 -CH 2 -], trimethylene [-CH 2 -CH 2 -CH 2 -], 1 ,2-dimethylethylene [-CH(CH 3 )-CH(CH 3 )-] and isopropylidene [-C(CH 3 ) 2 -].
- Halogen within the meaning of the invention is bromine, chlorine or fluorine.
- 3-7C-Cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl, cyclobutyl and cyclopentyl are preferred.
- 3-7C-Cycloalkylmethyl represents a methyl radical which is substituted by one of the abovementioned 3-7C-cycloalkyl radicals.
- the 3-5C-cycloalkyImethyl radicals cyclopropylmethyl, cyclobutyl- methyl and cyclopentylmethyl may be mentioned.
- 1-4C-Alkoxycarbonyl represents a carbonyl group to which one of the abovementioned 1-4C-alkoxy radicals is bonded. Examples which may be mentioned are the methoxycarbonyl [CH 3 0-C(0)-] and the ethoxycarbonyl [CH 3 CH 2 0-C(0)-] radicals.
- 1-4C-Alkylcarbonyloxy represents a carbonyloxy group to which one of the abovementioned 1-4C-alkyl radicals is bonded.
- An example which may be mentioned is the acetoxy radical [CH 3 C(0)-0-].
- mono- or di-1-4C-alkylamino radicals contain one or two of the above- mentioned 1-4C-alkyl radicals.
- Di-1-4C-alky!amino is preferred and here, in particular, dimethyl-, di- ethyl- or diisopropylamino.
- mono- or di-1-4C-alkylaminocarbonyl radicals contain one of the abovementioned mono- or di-1-4C-alkylamino radicals. Examples which may be mentioned are the N-methyl-, the N,N-dimethyl-, the N-ethyl-, the N-propyl-, the N,N-diethyl- and N-isopropylaminocarbonyi radicals.
- Ar-1-4C-alkyl represents one of the abovementioned 1-4C-alkyl radicals substituted by Ar.
- R6- and R18-substituted phenyl radicals which may be mentioned are 3-aminosulfonyl-4- chlorophenyl, 3-methoxycarbonyl-5-fluorophenyl, 3-fluoro-4-methoxycarbonylphenyl, 5-amino-3- methoxycarbonylphenyl, 5-amino-3-carboxyphenyl, 3-amino-4-carboxyphenyl, 3-amino-4- methoxycarbonylphenyl, 5-chloro-3-methoxycarbonylphenyl, 5-bromo-3-methoxycarbonylphenyl, 5-bromo-3-carboxyphenyl, 4-bromo-3-carboxyphenyl, 3-bromo-4-carboxyphenyl, 4-bromo-3- methoxycarbonylphenyl, 3-carboxy-5-hydroxyphenyl, 3-carboxy-5-methylphenyl, , 3-ethoxycarbonyl-5- nitropheny
- Possible salts for compounds of the formula I - depending on substitution - are all acid addition salts or all salts, with bases. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids and bases customarily used in pharmacy.
- water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, suifuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, it being possible to employ the acids in salt preparation - depending on whether a mono- or polybasic acid is concerned and depending on which salt is desired - in an equimolar quantitative ratio or one differing therefrom.
- acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid,
- salts with bases are also suitable.
- examples of salts with bases which may be mentioned are alkali metal (lithium, sodium, potassium) or calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidinium salts, where here too the bases are employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
- Pharmacologically intolerable salts which can initially be obtained, for example, as process products in the preparation of the compounds according to the invention on an industrial scale are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
- the compounds according to the invention and their salts when they are isolated, for example, in crystalline form, can contain various amounts of solvents.
- the invention therefore also comprises all solvates and in particular all hydrates of the compounds of the formula I, and also all solvates and in particular all hydrates of the salts of the compounds of the formula I.
- R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycIoalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R3 is hydrogen
- R31 is hydrogen
- R4 is hydrogen or 1-2C-alkyl
- R5 is hydrogen
- R51 is hydrogen, or in which
- R6 is S0 2 N(R7)R8, COOR9, CON(R10)R11 or a tetrazol-5-yl radical substituted by R15, where
- R7 and R8 independently of one another are hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cyc!oa!kylmethyl, or a phenyl radical which is unsubstituted or substituted by R12 and/or R13, or where R7 and R8 together and including the nitrogen atom to which both are bonded are a 1-piperidyl or 4-morpholinyl radical,
- R9 is hydrogen, 1-7C-alkyl or 3-7C-cycloalkylmethyl, and where either
- R10 and R11 independently of one another are hydrogen or 1-7C-alkyl or
- R10 is hydrogen
- R11 is a phenyi radical which is unsubstituted or substituted by R12 and/or R13 or a pyridyl radical which is unsubstituted or substituted by R14, where R12 is hydroxyl, halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R13 is hydroxyl, halogen, nitro, cyano, carboxyl, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyloxy or completely or predominantly fluorine- substituted 1-4C-alkoxy,
- R14 is halogen, 1-4C-alkoxy, 1-4C-alkyl, trifluoromethyl or completely or predominantly fluorine-substituted 1-4C-alkoxy,
- R15 is hydrogen, 1-4C-alkyl, 5-7C-cycloalkyl, 3-7C-cycloalkylmethyl or Ar-1-2C-alkyl, where Ar is a phenyl radical which is unsubstituted or substituted by R16 and
- R16 is 1-2C-alkyl or 1-2C-alkoxy
- R18 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy
- the salts, the N-oxides and the salts of the N-oxides of these compounds are 1-2C-alkyl or 1-2C-alkoxy
- R18 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy
- R1 is 1-2C-alkoxy
- R2 is 1-2C-alkoxy
- R3, R31 , R4, R5 and R51 are hydrogen
- R6 is S0 2 N(R7)R8, COOR9, CON(R10)R11 or an R15-substituted tetrazol-5-yl radical, where
- R7 and R8 independently of one another are hydrogen, 1-4C-alkyl or a phenyl radical which is unsubstituted or substituted by R13, ; ' R9 is hydrogen, 1-7C-alkyl or 3-7C-cycloalkylmethyl, and where either R10 and R11 independently of one another are hydrogen or 1-4C-alkyl, or
- R10 is hydrogen
- R11 is a phenyl radical which is unsubstituted or substituted by R13 or a pyridyl radical which is unsubstituted or substituted by R14, where
- R13 is halogen, nitro, cyano, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxy- carbonyl, 1-4C-alkylcarbonyloxy or completely or predominantly fluorine-substituted 1-4C- alkoxy,
- R14 is halogen, 1-4C-alkoxy, 1-4C-alkyl or trifluoromethyl
- R15 is hydrogen, 1-4C-alkyI or 4-methoxyphenyI
- R18 is halogen, nitro, 1-4C-alkyI or 1-4C-alkoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
- Preferred compounds of the formula I are those in which
- R1 is 1-2C-aikoxy
- R2 is 1-2C-alkoxy
- R3, R31 , R4, R5 and R51 are hydrogen
- R6 is S0 2 N(R7)R8, COOR9 or CON(R10)R11 , where
- R7 and R8 independently of one another are hydrogen or 1-4C-alkyl
- R9 is hydrogen or 1-4C-aikyl
- R10 and R11 independently of one another are hydrogen or 1-4C-alkyl, R18 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy, or the salts, the N-oxides and the salts of the N-oxides of this compound.
- Particularly preferred compounds of the formula I are those in which R1 is methoxy, R2 is methoxy,
- R3, R31 , R4, R5 and R51 are hydrogen
- R6 is COOR9, where R9 is 1-4C-aIkyl, R18 is nitro, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
- the compounds of the formula I are chiral compounds having chiral centers in positions 4a and 10b and, depending on the meaning of the substituents R3, R31 , R4, R5 and R51 , further chiral centers in the positions 1 , 2, 3 and 4.
- the invention therefore comprises ail conceivable pure diastereomers and pure enantiomers and their mixtures in any mixing ratio, including the racemates.
- the compounds of the formula I are preferred in which the hydrogen atoms in positions 4a and 10b are cis to one another.
- the pure cis enantiomers are particularly preferred.
- particularly preferred compounds of the formula I are those in which positions 4a and 10b have the same absolute configuration as the compound (-)-cis-1 ,2-dimethoxy-4-(2-aminocyclohexyl)benzene employable as a starting compound and having
- the enantiomers can be separated in a manner known per se (for example by preparation and separation of appropriate diastereoisomeric compounds).
- an enantiomer separation is carried out at the stage of the starting compounds of the formula IV
- racemic compounds of the formula IV for example by means of salt formation of the racemic compounds of the formula IV with optically active carboxylic acids.
- optically active carboxylic acids examples which may be mentioned in this connection are the enantiomeric forms of mandelic acid, tartaric acid, O,0'-dibenzoyltartaric acid, camphoric acid, quinic acid, glutamic acid, malic acid, camphorsulfonic acid, 3-bromocamphorsulfonic acid, ⁇ -methoxyphenylacetic acid, ⁇ -methoxy- -trifluoromethylphenylacetic acid and 2-phenylpropionic acid.
- enantiomeri- cally pure starting compounds of the formula IV can also be prepared via asymmetric syntheses.
- Reaction schemes 2 and 3 show preparation processes for compounds of the formula I in which R1 , R2, R3, R31 , R4, R5, R51 and R18 have the meanings indicated above and R6 is a R15- substituted tetrazol-5-yl radical.
- reaction scheme 1 shows, the compounds of the formula I in which R1, R2, R3, R31 , R4, R5, R51 and R18 have the meanings indicated above and R6 is not a R15-substituted tetrazol-5-yl radical, but is one of the other abovementioned meanings, are prepared from the compounds of the formula II by a cyclocondensation reaction.
- cyclocondensation is carried out in a manner known per se to the person skilled in the art according to Bischler-Napieralski (e.g. as described in J. Chem. Soc, 1956, 4280-4282) in the presence of a suitable condensing agent, such as polyphosphoric acid, phosphorus pentachioride, phosphorus pen- toxide or preferably phosphorus oxychloride, in a suitable inert solvent, e.g.
- the compounds of the formula II are obtained, for their part, by reaction of the compounds of the formula IV with compounds of the formula III, where X is a suitable leaving group, preferably a chlorine atom.
- X is a suitable leaving group, preferably a chlorine atom.
- the acylation or benzoylation is carried out as described in the following examples or as in J. Chem. Soc. (C), 1971 , 1805-1808.
- compounds of the formula II can also be prepared from the corresponding compounds of the formula IV and compounds of the formula III in which X is hydroxyl, by reaction with amide bond linking reagents known to the person skilled in the art.
- amide bond linking reagents known to the person skilled in the art which may be mentioned are, for example, the carbodiimides (e.g. dicyclohexylcarbodiimide), azodicarboxylic acid derivatives (e.g. di- ethyl azodicarboxylate), uranium salts [e.g. 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetra- fluoroborate] and N,N'-carbonyldiimidazole.
- carbodiimides e.g. dicyclohexylcarbodiimide
- azodicarboxylic acid derivatives e.g. di- ethyl azodicar
- This alternative preparation process is particularly suitable for the preparation of compounds of the formula II in which R18 is amino or hydroxyl.
- Reaction scheme 2 shows one of the possible preparation routes for compounds of the formula I in which R1 , R2, R3, R31 , R4, R5, R51 and R18 have the meanings indicated above and R6 is a tetrazol- 5-yI radical substituted by a radical R15 (R15 ⁇ hydrogen).
- R1 , R2, R3, R31 , R4, R5, R51 and R18 have the meanings indicated above and R6 is a tetrazol- 5-yI radical substituted by a radical R15 (R15 ⁇ hydrogen).
- R15 R15 ⁇ hydrogen
- reaction scheme 3 shows a preparation process for compounds of the formula I which is alternative to reaction scheme 2, in which R1 , R2, R3, R31 , R4, R5, R51 and R18 have the meanings indicated above and R6 is a tetrazol-5-yl radical substituted by a radical R15 (R15 ⁇ hydrogen).
- R6 is cyano
- the compounds of the formula I in which R6 is cyano are in turn obtained by cyclocondensation reaction from the corresponding compounds of the formula II.
- the compounds of the formula II are obtained by reaction of the compounds of the formula IV with compounds of the formula III in which X is a suitable leaving group, preferably a chlorine atom.
- compounds of the formula I in which R1 , R2, R3, R31 , R4, R5, R51 and R18 have the meanings indicated above and R6 is a tetrazol-5-yl radical substituted by a radical R15 (R15 ⁇ hydrogen) can also be prepared by an alkylation reaction from the corresponding compounds of the formula I in which R15 is hydrogen.
- the alkylation reaction is expediently carried out analogously to the methods known to the person skilled in the art, e.g.
- Reaction scheme 4 discloses a possible preparation route for compounds of the formula III in which X is a suitable leaving group, preferably a chlorine atom, R18 has the abovementioned meanings and R6 is a tetrazol-5-yl radical substituted by a radical R15 (R15 ⁇ hydrogen).
- X is a suitable leaving group, preferably a chlorine atom
- R18 has the abovementioned meanings
- R6 is a tetrazol-5-yl radical substituted by a radical R15 (R15 ⁇ hydrogen).
- 2-, 3- or 4-cyanobenzoates 2-, 3- or 4-(1 H and 2H-tetrazoI-5-yl)benzoic acid ester derivatives unsubstituted in the tetrazole moiety are obtained in a manner known to the person skilled in the art, e.g. by reaction with alkali metal azides and halogen salts of ammonia.
- the compounds of the formula I can be converted, if desired, into their N-oxides, for example with the aid of hydrogen peroxide in methanol or with the aid of m-chloroperoxybenzoic acid in di- chloromethane.
- the person skilled in the art is familiar on the basis of his/her expert knowledge with the reaction conditions which are specifically necessary for carrying out the N-oxidation.
- the compounds of the formula IV can be prepared, for example, from compounds of the formula V,
- R1 , R2, R3, R31 , R4, R5 and R51 have the abovementioned meanings, by reduction of the nitro group.
- the reduction can be carried out, for example, by catalytic hydrogenation, e.g. in the presence of Ra- ney nickel, in a lower alcohol such as methanol or ethanol at room temperature and under normal or elevated pressure.
- a catalytic amount of an acid such as, for example, hydrochloric acid
- the reduction is carried out using metals such as zinc or iron with organic acids such as acetic acid or mineral acids such as hydrochloric acid.
- the compounds of the formula IV in which R1 , R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 together represent an additional bond can be prepared from the corresponding compounds of the formula V by selective reduction of the nitro group in a manner known to the person skilled in the art, for example in the presence of Raney nickel in a lower alcohol as solvent using hydra- zine hydrate as a hydrogen donor.
- the compounds of the formula V in which R1 , R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 are hydrogen, are either known or can be prepared from corresponding compounds of the formula V in which R5 and R51 together are an additional bond.
- the reaction can be carried out in a manner known to the person skilled in the art, preferably by hydrogenation in the presence of a catalyst, such as, for example, palladium on active carbon, e.g. as described in J. Chem. Soc. (C), 1971 , 1805-1808.
- R3, R31 and R4 have the meanings mentioned above.
- R1 and R2 have the meanings indicated above, are either known or can be prepared in a manner known to the person skilled in the art, as described, for example, in Ber. Dtsch. Chem. Ges. 1925, 58, 203.
- the isolation and purification of the substances according to the invention is carried out in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the resulting residue from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on suitable support material.
- Salts are obtained by dissolving the free compound in a suitable solvent (e.g. a ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, an ether, such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added.
- the salts are obtained by filtering, reprecipitating, precipitating with a nonsolvent for the addition salt or by evaporating the solvent. Salts obtained can be converted by alkalization or by acidification into the free compounds, which in turn can be converted into salts. In this way, pharmacologically intolerable salts can be converted into pharmacologically tolerable salts.
- (+/-)-cis-1 ,2-dimethoxy-4-(2-nitrocyclohexyl)benzene and 120 g of zinc powder or granules are suspended in 1300 ml of ethanol. 220 ml of acetic acid are added dropwise at boiling heat. The precipitate is filtered off with suction and washed with ethanol, and the filtrate is concentrated under reduced pressure. The residue is taken up in hydrochloric acid and extracted with toluene. The aqueous phase is rendered alkaline using 50% strength sodium hydroxide solution, the precipitate is filtered off with suction and the filtrate is extracted with toluene. The organic phase is dried using sodium sulfate and concentrated. 98 g of the title compound are obtained as a crystallizing oil.
- the compounds according to the invention have valuable pharmacological properties which make them commercially utilizable.
- selective cyclic nucleotide phosphodiesterase (PDE) inhibitors namely of type 4
- they are suitable on the one hand as bronchial therapeutics (for the treatment of airway obstructions on account of their dilating but also on account of their respiratory rate- or respiratory drive- increasing action) and for the elimination of erectile dysfunction on account of the vasodilating action, but on the other hand especially for the treatment of disorders, in particular of inflammatory nature, e.g.
- the compounds according to the invention are distinguished here by low toxicity, good en- teral absorption (high bioavailability), a large therapeutic breadth and the absence of significant side- effects.
- the compounds according to the invention can be employed in human and veterinary medicine and therapeutics, where they can be used, for example, for the treatment and prophylaxis of the following illnesses: acute and chronic (in particular inflammatory and allergen-induced) airway disorders of various origins (bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD); dermatoses (especially of proliferative, inflammatory and allergic type) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritus in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea
- disorders of the arthritis type rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic conditions
- disorders of the immune system AIDS, multiple sclerosis
- graft-versus-host reactions transplant rejection reactions
- symptoms of shock [septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respiratory distress syndrome)]
- generalized inflammations in the gastrointestinal area Crohn's disease and ulcerative colitis
- disorders of the heart which can be treated by PDE inhibitors, such as, for example, cardiac insuffici
- the compounds according to the invention can be employed for the treatment of diabetes insipidus and disorders in connection with disturbances of brain metabolism, such as, for example, cerebral senility, senile dementia (Alzheimer's dementia), multiin- farct dementia or alternatively disorders of the CNS, such as, for example, depressions or arterioscle- rotic dementia.
- brain metabolism such as, for example, cerebral senility, senile dementia (Alzheimer's dementia), multiin- farct dementia or alternatively disorders of the CNS, such as, for example, depressions or arterioscle- rotic dementia.
- the invention further relates to the compounds according to the invention for use in the treatment of mammals, including man, which are suffering from one of the abovementioned illnesses.
- the process comprises administering to the sick mammal a therapeutically efficacious and pharmacologically tolerable amount of one or more of the compounds according to the invention.
- the invention further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of illnesses, in particular the illnesses mentioned.
- the invention likewise relates to the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the illnesses mentioned.
- Medicaments for the treatment and/or prophylaxis of the illnesses mentioned which contain one or more of the compounds according to the invention, are furthermore a subject of the invention.
- a further subject of the invention is a commercial product, consisting of a customary secondary pack, a primary pack containing the medicament (for example an ampoule or a blister pack) and, if desired, a pack insert, the medicament exhibiting antagonistic action against cyclic nucleotide phosphodiesterases of type 4 (PDE4) and leading to the attenuation of the symptoms of illnesses which are connected with cyclic nucleotide phosphodiesterases of type 4, and the suitability of the medicament for the prophylaxis or treatment of illnesses which are connected with cyclic nucleotide phosphodiesterases of type 4 being indicated on the secondary pack or on the pack insert of the commercial product, and the medicament containing one or more compounds of the formula I according to the invention.
- the secondary pack, the primary pack containing the medicament and the pack insert otherwise comply with what would be regarded as standard to the person skilled in the art for medicaments of this type.
- the medicaments are prepared by processes which are known per se and familiar to the person skilled in the art.
- the person skilled in the art is familiar on the basis of his/her expert knowledge with the excipients which are suitable for the desired pharmaceutical formulations.
- solvents gel-forming agents, ointment bases and other active compound vehicles
- the compounds according to the invention are preferably also administered by inhalation in the form of an aerosol; the aerosol particles of solid, liquid or mixed composition preferably having a diameter of 0.5 to 10 ⁇ m, advantagously of 2 to 6 ⁇ m.
- Aerosol generation can be carried out, for example, by pressure-driven jet atomizers or ultrasonic atomizers, but advantageously by propellant-driven metered aerosols or propellant-free administration of micronized active compounds from inhalation capsules.
- the administration forms additionally contain the required excipients, such as, for example, propellants (e.g. Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in the case of powder inhalers) or, if appropriate, further active compounds.
- propellants e.g. Frigen in the case of metered aerosols
- surface-active substances e.g. Frigen in the case of metered aerosols
- emulsifiers emulsifiers
- stabilizers emulsifiers
- preservatives e.g., emulsifiers, stabilizers, preservatives
- flavorings e.g. lactose in the case of powder inhalers
- fillers e.g. lactose in the case of powder inhalers
- the compounds according to the invention are in particular used in the form of those medicaments which are suitable for topical application.
- suitable pharmaceutical formulations which may be mentioned are, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.
- the medicaments according to the invention are prepared by processes known per se. Dosage of the active compounds takes place in the order of magnitude customary for PDE inhibitors. Thus topical application forms (such as, for example, ointments) for the treatment of dermatoses contain the active compounds in a concentration of, for example, 0.1-99%.
- the dose for administration by inhalation is customarily between 0.1 and 3 mg per day.
- the customary dose in the case of systemic therapy (p.o. or i.v.) is between 0.03 and 3 mg per kilogram per day.
- the second messenger cyclic AMP (cAMP) is well-known for inhibiting inflammatory and immunocom- petent cells.
- the PDE4 isoenzyme is broadly expressed in cells involved in the initiation and propagation of inflammatory diseases (H Tenor and C Schudt, in obviouslyPhosphodiesterase Inhibitors", 21-40, sentThe Handbook of Immunopharmacology", Academic Press, 1996), and its inhibition leads to an increase of the intracellular cAMP concentration and thus to the inhibition of cellular activation (JE Souness et al., Immunopharmacology 47: 127-162, 2000).
- Examples are the superoxide production of neutrophilic (C Schudt et al., Arch Pharmacol 344: 682-690, 1991 ) or eosinophilic (A Hatzelmann et al., Brit J Pharmacol 114: 821-831 , 1995) granulocytes, which can be measured as lu- minol-enhanced chemiluminescence, or the synthesis of tumor necrosis factor- ⁇ in monocytes, macro- phages or dendritic cells (Gantner et al., Brit J Pharmacol 121 : 221-231 , 1997, and Pulmonary Pharmacol Therap 12: 377-386, 1999).
- neutrophilic C Schudt et al., Arch Pharmacol 344: 682-690, 1991
- eosinophilic A Hatzelmann et al., Brit J Pharmacol 114: 821-831 , 1995
- granulocytes which can be measured as lu- minol-enhance
- PDE4 activity was determined as described by Thompson et al. (Adv Cycl Nucl Res 10: 69-92, 1979) with some modifications (Bauer and Schwabe, Naunyn-Schmiedeberg's Arch Pharmacol 311 : 193-198, 1980).
- the assay mixture contained 20 mM Tris (pH 7.4), 5 mM MgCI 2 , 0.5 ⁇ M cAMP, [ 3 H]cAMP (about 30,000 cpm/assay), the test compound and an aliquot of cytosol from human neutrophils which mainly contains PDE4 activity as described by Schudt et al.
- the reaction was started by the addition of substrate (cAMP) and the assays were incubated for further 15 min at 37°C. 50 ⁇ l of 0.2 N HCI was added to stop the reaction and the assays were left on ice for about 10 min.
- the assays were loaded on QAE Sephadex A-25 (1 ml bed volume). The columns were eluted with 2 ml of 30 M ammonium formiate (pH 6.0) and the eluate was counted for radioactivity.
- Results were corrected for blank values (measured in the presence of denatured protein) which were below 5 % of total radioactivity.
- the amount of cyclic nucleotides hydrolyzed did not exceed 30 % of the original substrate concentration.
- the IC 50 -values for the compounds according to the invention for the inhibition of the PDE4 activity were determined from the concentration- inhibition curves by nonlinear-regression.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001281965A AU2001281965A1 (en) | 2000-07-14 | 2001-07-07 | Novel 6-phenylphenanthridines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00115278 | 2000-07-14 | ||
EP00115278.4 | 2000-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002005616A1 true WO2002005616A1 (en) | 2002-01-24 |
WO2002005616A8 WO2002005616A8 (en) | 2002-02-14 |
Family
ID=8169260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/007829 WO2002005616A1 (en) | 2000-07-14 | 2001-07-07 | Novel 6-phenylphenanthridines |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001281965A1 (en) |
WO (1) | WO2002005616A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019945A1 (en) * | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
WO2004019944A1 (en) * | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
WO2004050631A1 (en) * | 2002-12-04 | 2004-06-17 | Wyeth | Substituted dihydrophenanthridinesul fonamides |
WO2004072046A2 (en) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
WO2005012253A1 (en) * | 2003-07-31 | 2005-02-10 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
WO2005012252A1 (en) * | 2003-07-31 | 2005-02-10 | Altana Pharma Ag | Novel 6-phenylphenantridines |
WO2005077906A1 (en) | 2004-02-18 | 2005-08-25 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
WO2005085225A1 (en) | 2004-03-03 | 2005-09-15 | Altana Pharma Ag | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors |
WO2006028875A1 (en) * | 2004-09-02 | 2006-03-16 | Wyeth | Phenanthridine carbonyl phenols as cytokine modulators |
WO2006027345A2 (en) * | 2004-09-08 | 2006-03-16 | Altana Pharma Ag | Novel 3-thia-10-aza-phenanthrene derivatives |
WO2006092422A1 (en) * | 2005-03-02 | 2006-09-08 | Nycomed Gmbh | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
WO2006095009A1 (en) * | 2005-03-09 | 2006-09-14 | Nycomed Gmbh | Amido-substituted 6-phenylphenanthridines |
US7723391B2 (en) | 2007-10-04 | 2010-05-25 | Roche Palo Alto Llc | Cyclopropyl aryl amide derivatives and uses thereof |
US7838521B2 (en) | 2004-09-08 | 2010-11-23 | Nycomed Gmbh | 3-oxa-10-aza-phenanthrenes |
TWI468411B (en) * | 2009-12-18 | 2015-01-11 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
NO340563B1 (en) * | 2016-09-05 | 2017-05-15 | Takeda Gmbh | New salts of 6-heterocyclyl-substituted hexahydrophenanthridine derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028131A1 (en) * | 1996-01-31 | 1997-08-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New phenanthridines |
WO1997035854A1 (en) * | 1996-03-26 | 1997-10-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel phenanthridines substituted in the 6 position |
WO1999005112A1 (en) * | 1997-07-25 | 1999-02-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-alkylphenanthridines |
WO1999005111A1 (en) * | 1997-07-25 | 1999-02-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel tetrazole derivatives |
WO1999005113A1 (en) * | 1997-07-25 | 1999-02-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-phenylphenanthridines |
-
2001
- 2001-07-07 AU AU2001281965A patent/AU2001281965A1/en not_active Abandoned
- 2001-07-07 WO PCT/EP2001/007829 patent/WO2002005616A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028131A1 (en) * | 1996-01-31 | 1997-08-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New phenanthridines |
WO1997035854A1 (en) * | 1996-03-26 | 1997-10-02 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel phenanthridines substituted in the 6 position |
WO1999005112A1 (en) * | 1997-07-25 | 1999-02-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-alkylphenanthridines |
WO1999005111A1 (en) * | 1997-07-25 | 1999-02-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel tetrazole derivatives |
WO1999005113A1 (en) * | 1997-07-25 | 1999-02-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-phenylphenanthridines |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632844B2 (en) | 2002-08-29 | 2009-12-15 | Nycomed Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
US7423046B2 (en) | 2002-08-29 | 2008-09-09 | Nycomed Gmbh | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
JP2005539043A (en) * | 2002-08-29 | 2005-12-22 | アルタナ ファルマ アクチエンゲゼルシャフト | 2-hydroxy-6-phenylphenanthridine as PDE4 inhibitor |
JP2006508913A (en) * | 2002-08-29 | 2006-03-16 | アルタナ ファルマ アクチエンゲゼルシャフト | 3-hydroxy-6-phenylphenanthridine as a PDE4 inhibitor |
WO2004019945A1 (en) * | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
AU2003255493B2 (en) * | 2002-08-29 | 2009-02-19 | Takeda Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
AU2003255493B8 (en) * | 2002-08-29 | 2009-03-26 | Takeda Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
AU2003273805B8 (en) * | 2002-08-29 | 2010-06-17 | Takeda Gmbh | 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
US7329676B2 (en) | 2002-08-29 | 2008-02-12 | Nycomed Gmbh | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
AU2003273805B2 (en) * | 2002-08-29 | 2009-10-01 | Takeda Gmbh | 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors |
US8202880B2 (en) | 2002-08-29 | 2012-06-19 | Nycomed Gmbh | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors |
WO2004019944A1 (en) * | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
US6894061B2 (en) | 2002-12-04 | 2005-05-17 | Wyeth | Substituted dihydrophenanthridinesulfonamides |
WO2004050631A1 (en) * | 2002-12-04 | 2004-06-17 | Wyeth | Substituted dihydrophenanthridinesul fonamides |
WO2004072046A3 (en) * | 2003-02-12 | 2004-10-21 | Carex S A | Quinoline derivatives and their use for modulation of lxr activity |
WO2004072046A2 (en) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
WO2005012252A1 (en) * | 2003-07-31 | 2005-02-10 | Altana Pharma Ag | Novel 6-phenylphenantridines |
WO2005012253A1 (en) * | 2003-07-31 | 2005-02-10 | Altana Pharma Ag | Novel 6-phenylphenanthridines |
US8329906B2 (en) | 2004-02-18 | 2012-12-11 | Nycomed Gmbh | Guanidinyl-substituted hydroxy-6-phenylphenanthridines |
US7585872B2 (en) | 2004-02-18 | 2009-09-08 | Nycomed Gmbh | Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors |
WO2005077906A1 (en) | 2004-02-18 | 2005-08-25 | Altana Pharma Ag | Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors |
US8318944B2 (en) | 2004-03-03 | 2012-11-27 | Nycomed Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
US8455653B2 (en) | 2004-03-03 | 2013-06-04 | Takeda Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
US9962377B2 (en) | 2004-03-03 | 2018-05-08 | Takeda Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
JP2007526283A (en) * | 2004-03-03 | 2007-09-13 | アルタナ ファルマ アクチエンゲゼルシャフト | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
US9387205B2 (en) | 2004-03-03 | 2016-07-12 | Takeda Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
US9149479B2 (en) | 2004-03-03 | 2015-10-06 | Takeda Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
US8883818B2 (en) | 2004-03-03 | 2014-11-11 | Takeda Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
EP2589599A1 (en) | 2004-03-03 | 2013-05-08 | Takeda GmbH | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
WO2005085225A1 (en) | 2004-03-03 | 2005-09-15 | Altana Pharma Ag | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors |
US8324391B2 (en) | 2004-03-03 | 2012-12-04 | Nycomed Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
JP4801039B2 (en) * | 2004-03-03 | 2011-10-26 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
US8003798B2 (en) | 2004-03-03 | 2011-08-23 | Nycomed Gmbh | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
JP2011074094A (en) * | 2004-03-03 | 2011-04-14 | Nycomed Gmbh | New hydroxy-6-heteroarylphenanthridine and pharmaceutical composition containing the same |
US7585871B2 (en) | 2004-09-02 | 2009-09-08 | Wyeth | Phenanthridine carbonyl phenols |
WO2006028875A1 (en) * | 2004-09-02 | 2006-03-16 | Wyeth | Phenanthridine carbonyl phenols as cytokine modulators |
US7589205B2 (en) | 2004-09-08 | 2009-09-15 | Nycomed Gmbh | 3-thia-10-aza-phenanthrene derivatives |
US7838521B2 (en) | 2004-09-08 | 2010-11-23 | Nycomed Gmbh | 3-oxa-10-aza-phenanthrenes |
WO2006027345A3 (en) * | 2004-09-08 | 2006-08-31 | Altana Pharma Ag | Novel 3-thia-10-aza-phenanthrene derivatives |
JP2008512367A (en) * | 2004-09-08 | 2008-04-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel 3-thia-10-aza-phenanthrene derivatives |
AU2005281703B2 (en) * | 2004-09-08 | 2011-11-17 | Takeda Gmbh | Novel 3-thia-10-aza-phenanthrene derivatives |
WO2006027345A2 (en) * | 2004-09-08 | 2006-03-16 | Altana Pharma Ag | Novel 3-thia-10-aza-phenanthrene derivatives |
US8354535B2 (en) | 2005-03-02 | 2013-01-15 | Nycomed Gmbh | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives |
EP2189454A1 (en) | 2005-03-02 | 2010-05-26 | Nycomed GmbH | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
EP2295423A1 (en) * | 2005-03-02 | 2011-03-16 | Nycomed GmbH | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
WO2006092422A1 (en) * | 2005-03-02 | 2006-09-08 | Nycomed Gmbh | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
JP2008531655A (en) * | 2005-03-02 | 2008-08-14 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
US8754218B2 (en) | 2005-03-02 | 2014-06-17 | Takeda Gmbh | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives |
US8829189B2 (en) | 2005-03-02 | 2014-09-09 | Takeda Gmbh | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives |
US7718668B2 (en) | 2005-03-02 | 2010-05-18 | Nycomed Gmbh | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives |
EA015376B1 (en) * | 2005-03-02 | 2011-08-30 | Никомед Гмбх | SALTS OF 6-HETEROARYL-(1,2,3,4,4a,10b)-HEXAHYDROPHENANTHRIDINE DERIVATIVES AND USE THEREOF |
NO339416B1 (en) * | 2005-03-02 | 2016-12-12 | Takeda Gmbh | New salts of 6-heterocyclyl-substituted hexahydrophenanthridine derivatives |
WO2006095009A1 (en) * | 2005-03-09 | 2006-09-14 | Nycomed Gmbh | Amido-substituted 6-phenylphenanthridines |
US7723391B2 (en) | 2007-10-04 | 2010-05-25 | Roche Palo Alto Llc | Cyclopropyl aryl amide derivatives and uses thereof |
US9018175B2 (en) | 2009-12-18 | 2015-04-28 | Takeda Gmbh | 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives |
TWI468411B (en) * | 2009-12-18 | 2015-01-11 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
NO340563B1 (en) * | 2016-09-05 | 2017-05-15 | Takeda Gmbh | New salts of 6-heterocyclyl-substituted hexahydrophenanthridine derivatives |
Also Published As
Publication number | Publication date |
---|---|
AU2001281965A1 (en) | 2002-01-30 |
WO2002005616A8 (en) | 2002-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6476025B1 (en) | Phenylphennanthridines with PDE-IV inhibiting activity | |
EP0998460B1 (en) | Novel tetrazole derivatives | |
US20060116518A1 (en) | Novel phenanthridines | |
US6534518B1 (en) | Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity | |
WO2002005616A1 (en) | Novel 6-phenylphenanthridines | |
EP1147103B1 (en) | Phenantrhridine-n-oxides with pde-iv inhibiting activity | |
US6538005B2 (en) | Phenanthridine-N-oxides with PDE-IV inhibiting activity | |
EP1303506B1 (en) | 6-heteroarylphenanthridines | |
AU2001283935A1 (en) | Novel 6-heteroarylphenanthridines | |
WO2002006238A1 (en) | Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines | |
AU782908B2 (en) | Phenanthridine-N-oxides | |
US20060189641A1 (en) | Novel 6-phenlyphenanthridines | |
WO2002006239A1 (en) | Phenanthridine n-oxides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BG BR CA CN CO CZ EC EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK UA US VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AU BA BG BR CA CN CO CZ EC EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK UA US VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 04/2002 UNDER (51) REPLACE "NOT CLASSIFIED" BY "C07D221/12, 401/10, A61K 31/473, A61P 11/06" |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |